Chronic inflammatory demyelinating polyneuropathy(CIDP)is a treatable immune-mediated disorder,which causes in its typical form,symmetric proximal and distal weakness with large fibre sensory impairment involving the four limbs.There are currently three main first-line therapeutic options for CIDP.These consist of corticosteroids,immunoglobulins and plasma exchanges(PE)which have all been found effective in a
展开▼
